Audit Trail Review by Exception: Reducing Reviewer Burden Without Weakening Detection
Faculty: Carolyn Troiano | Product ID: FDB3242
- Date:07/23/2026 12:00 PM - 07/23/2026 01:30 PM
- Location Online Event
Description
In FDA and globally regulated environments, audit trail review has become one of the most resource-intensive and misunderstood compliance activities. Many organizations continue to apply manual, exhaustive review approaches that generate reviewer fatigue, slow batch release, and dilute focus on truly critical events.
This session explores how to implement a risk-based, “review by exception” strategy that reduces reviewer burden while strengthening the ability to detect meaningful compliance, data integrity, cybersecurity, and operational risks. Attendees will learn how modern approaches aligned with FDA expectations, data integrity guidance, and risk-based validation principles can improve efficiency without sacrificing control.
The discussion will also address the role of AI-enabled analytics, automation, prioritizing risk, and ensuring human critical thinking remains the final guardrail for decision-making.
WHY YOU SHOULD ATTEND:
This webinar is intended for those involved in planning, execution and support of computer system validation activities, working in the FDA-regulated industries, including pharmaceutical, medical device, biologics, tobacco and tobacco-related products (e-liquids, e-cigarettes, pouch tobacco, cigars, etc.). Functions that are applicable include research and development, manufacturing, Quality Control testing, distribution, clinical trial management, sample labeling, adverse events management, and post-marketing surveillance. Whether involved in software development, testing, implementation, validation, maintenance or use of AI-enabled solutions, you will find a wealth of knowledge to enhance your ability to use these technologies with maximum effectiveness. Those using these systems, in particular, must understand their role as the human guardrail of AI, critically assessing the outcomes, making intelligent judgment calls, and ensuring better decisions. It’s not just about using these AI solutions, it’s about using them effectively and by critically thinking about your role and accountability to ensure you optimize quality, compliance, and ROI.
LEARNING OBJECTIVES:
- Learn how to reduce time spent on low-value audit trail review activities
- Understand how to focus reviewers on high-risk events and meaningful exceptions
- Explore FDA and global regulatory expectations related to audit trails and data integrity
- Identify common weaknesses that lead to reviewer overload and missed signals
- Discover how risk-based review models improve both efficiency and detection capability
- Understand how AI and automated analytics can support smarter exception identification
- Gain practical approaches that can be implemented across manufacturing, laboratory, clinical, and quality systems
- Improve inspection readiness while reducing operational burden and compliance bottlenecks
AREAS COVERED:
- Regulatory Expectations and Industry Drivers
- FDA, MHRA, EMA, and PIC/S expectations for audit trail review
- Relationship between audit trails, data integrity, and patient safety
- Common inspection observations and enforcement trends
- Evolution from checklist compliance to risk-based oversight
- Understanding the Purpose of Audit Trail Review
- What audit trails are intended to detect
- Critical vs. non-critical audit trail events
- Distinguishing signal from noise
- Why excessive review can weaken effectiveness
- Review by Exception Principles
- Defining a risk-based review-by-exception model
- Establishing meaningful exception criteria
- Risk ranking and prioritization methodologies
- Event categorization strategies
- High-Risk Events and Red Flags
- Unauthorized access or privilege escalation
- Data deletion, overwriting, or backdating
- Repeated failed login attempts
- Disabled audit trails or security controls
- Changes to critical parameters, specifications, or master data
- Suspicious sequence-of-events patterns
- Metadata inconsistencies and timing anomalies
- Reducing Reviewer Burden Without Losing Control
- Eliminating low-value manual review activities
- Automating repetitive detection tasks
- Reducing alert fatigue and false positives
- Optimizing workflows for reviewers and QA oversight
- Metrics for demonstrating effectiveness and efficiency
- Leveraging AI and Advanced Analytics
- Using AI to identify patterns, anomalies, and emerging risks
- Predictive detection vs. static review approaches
- AI limitations: hallucinations, bias, and performance drift
- Importance of explainability and defensible decision-making
- The human guardrail
- Integration with CSA and Modern Validation Approaches
- Aligning review-by-exception with U.S. Food and Drug Administration Computer Software Assurance (CSA) principles
- Critical thinking vs. rote verification
- Risk-based evidence generation
- Designing systems and workflows for smarter review
- Inspection Readiness and Defensibility
- Demonstrating rationale for exception criteria
- Documentation and SOP considerations
- Showing effectiveness during inspections
- Defending a risk-based approach to regulators
- Practical Implementation Roadmap
- Assessing current-state audit trail review processes
- Identifying quick wins and automation opportunities
- Governance, training, and change management
- Building a sustainable review-by-exception program
- Future State of Audit Trail Review
- AI-assisted continuous monitoring
- Real-time detection and escalation
- Cross-system risk intelligence
- Transition from reactive review to proactive quality oversight
WHO SHOULD ATTEND:
- Information Technology Analysts
- Information Technology Developers and Testers
- QC/QA Managers and Analysts
- Analytical Chemists
- Compliance and Audit Managers
- Laboratory Managers
- Automation Analysts and Managers
- Manufacturing Specialists and Managers
- Supply Chain Specialists and Managers
- Regulatory Affairs Specialists
- Regulatory Submissions Specialists
- Clinical Data Analysts
- Clinical Data Managers
- Clinical Trial Sponsors
- Computer System Validation Specialists
- GMP Training Specialists
- Business Stakeholders/Subject Matter Experts
- Business System/Application Testers
- Business Stakeholders responsible for computer system validation planning, execution, reporting, compliance, maintenance and audit
- Consultants working in the life sciences industry who are involved in computer system implementation, validation and compliance
- Auditors engaged in internal inspection
This webinar will also benefit any vendors and consultants working in the life sciences industry who are involved in computer system implementation, validation and compliance. It will also help those in software development companies who support the life science industries.
Course Director: CAROLYN TROIANO
Carolyn Troiano has more than 45 years of experience in computer system validation in the pharmaceutical, medical device, biotechnology, tobacco, and other FDA-regulated industries. She is currently an independent consultant, advising companies on FDA compliance, Computer System Validation (CSV), and large-scale IT system implementation projects.
Carolyn participated in the FDA/Industry Partnership to develop 21 CFR Part 11, the FDA’s Guidance for Electronic Records and Electronic Signatures. During her career she has provided training, including CSV, 21 CFR Part 11, Data Integrity, and many other related compliance topics of interest to the life science industries.